BCM
SPRB

BML Capital Management’s Spruce Biosciences SPRB Stock Holding History

BML Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,958
Closed -$243K – 35
2022
Q4 		$243K Buy
+2,958
New +$248K 0.23% 24

Other funds holding SPRB

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BML Capital Management's SPRB Position: Q1 2023 in Review

BML Capital Management sold out of Spruce Biosciences (SPRB) in Q1 2023, closing a stake of 2,958 shares — an estimated $243K sold.

BML Capital Management first reported a position in SPRB in Q4 2022 and held it in 1 quarter. The position peaked at $243K in Q4 2022. 44 funds tracked by Wall St. Rank hold SPRB as of Q1 2023.

  • BML Capital Management reported no remaining Spruce Biosciences position as of Q1 2023 after selling out during the quarter.
  • BML Capital Management sold 2,958 Spruce Biosciences shares in Q1 2023, an estimated $243K.
  • BML Capital Management first reported a position in Spruce Biosciences in Q4 2022 and held it in 1 quarter.
  • BML Capital Management's Spruce Biosciences position peaked at $243K in Q4 2022.
  • 44 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2023.

Based on BML Capital Management's 13F filing for Q1 2023, filed 14 Apr 2023.